Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Cellectar BioSciences

NVIDIA

Super Micro Computer

Tesla

As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1.

Wall Street's top 5 stocks with the biggest upside in 2025

The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide. The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide.

mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMR

Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.

Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Moderna's (MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value.

Is Moderna Stock a Buy?

Summit Therapeutics

Uber

A five-bagger in only five years? Any investor would love to buy such a stock.

3 Stocks That Could Turn $1,000 into $5,000 by 2030

Broadcom

Eli Lilly

The incredible returns equity investors have seen in 2024, and over the past couple months for that matter, have been incredible.

This Feels Like the Post-Pandemic Rally. 3 Stocks to Buy If It Is

BioNTech SE

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

MicroStrategy Incorporated

Palantir Technologies

The Nasdaq is due to announce any changes to the Nasdaq 100 index as part of its annual reconstitution at 8 p.m. ET Friday.

Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped.

SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026. Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI.

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

Celanese

Dollar Tree

Intel

Walgreens

2024 has been a generally outstanding year for the stock market, with the S&P 500 (^GSPC 0.82%) up by nearly 30% year to date as of Dec. 11. However, not all stocks have performed nearly this well –- in fact, some components of the S&P 500 have underperformed the benchmark index by as much as 90 percentage points.

These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over

Biogen

Micron Technology

Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.

Analysts Predict These Will Be Next Year's Top 10 Stocks

Growing Incidence of Chronic and Infectious Diseases, Advancements in Synthetic Biology & Bioinformatics, Rising Demand for Personalized Medicine Growing Incidence of Chronic and Infectious Diseases, Advancements in Synthetic Biology & Bioinformatics, Rising Demand for Personalized Medicine

mRNA Vaccines and Therapeutics Industry Forecast to Generate Over $72 Billion in Revenues by 2032 - Breakdown by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region

Carisma Therapeutics Inc

Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies.

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Strong demand for mRNA-based vaccines and therapies continues to fuel market growth in diverse therapeutic areas, including oncology, infectious diseases, and rare genetic disorders. Strong demand for mRNA-based vaccines and therapies continues to fuel market growth in diverse therapeutic areas, including oncology, infectious diseases, and rare genetic disorders.

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider

Moderna, Inc. (NASDAQ:MRNA ) Piper Sandler 36th Annual Healthcare Conference December 5, 2024 10:30 AM ET Company Participants Stephane Bancel - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff Good morning, everyone. My name is Ted Tenthoff.

Moderna, Inc. (MRNA) Piper Sandler 36th Annual Healthcare Conference (Transcript)

The S&P 500 has hit record levels this year and many stocks have generated fantastic returns for investors. But there's been no shortage of struggling investments, either.

Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks of 2024?

Moderna, Inc. (NASDAQ:MRNA ) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Conference Call Participants Cory Kasimov - Evercore ISI Cory Kasimov Good afternoon, everyone. I'm Cory Kasimov, one of the senior biotech analysts here at Evercore ISI.

Moderna, Inc. (MRNA) 7th Annual Evercore ISI HealthCONx Conference - (Transcript)

Celsius Holdings

Century Aluminum

Concentrix Corporation 

Corsair Gaming

Sprinklr

Flagstar Financial Inc

GEO Group

Hims & Hers Health

Jefferies Financial Group Inc

Lumen Technologies

Marathon Digital Holdings

MGP Ingredients

Pitney Bowes

EchoStar

TG Therapeutics

Texas Pacific Land Trust

Titan

ViaSat

Difficult-to-short stocks often trade at artificially inflated, unsustainable prices.

20 stocks likely to lag the S&P 500 over the next year — for this one reason

DexCom

Lululemon Athletica

The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years.

These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over

Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed. The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.

Moderna: Optimistic Outlook Despite The Recent Sell-Off

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

Moderna to Present at Upcoming Conferences in December 2024

Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.

Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference

Moderna, Inc. (NASDAQ:MRNA ) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session.

Moderna, Inc. (MRNA) Presents at Jefferies London Healthcare Conference (Transcript)

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell today?

Is Moderna Stock A Sell With Deep Losses Projected For The Fourth Quarter?

The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.

News for Moderna Stock (MRNA)